EGFR and bone metastasis: Patients with brain metastasis (p = 0.025), liver metastasis (p = 0.012), bone metastasis (p = 0.014) and EGFR mutations (p = 0.033) who received combination therapy with PD-1 inhibitors and antiangiogenic drugs had shorter OS (Table 4 and Fig. 2B-E).